0001562762-22-000230 | 10-Q | XBRL Viewer

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2022	May 06, 2022
Document Type	10-Q
Entity Central Index Key	0001851657
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-41058
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line Two	Ste 3388
Entity Address, Address Line One	1717 Main St
Entity Address, City or Town	Dallas
Entity Address, Postal Zip Code	75201
Entity Address, State or Province	TX
Entity Tax Identification Number	86-2083865
Entity Registrant Name	Vaxxinity, Inc.
Entity Ex Transition Period	false
Local Phone Number	254
City Area Code	244-5739
Title of 12(b) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	VAXX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	No
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Class A Common Stock [Member]
Entity Common Stock, Shares Outstanding		112,120,585
Common Class B [Member]
Entity Common Stock, Shares Outstanding		13,874,132

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 124,766	$ 144,885
Amounts due from related parties	399	393
Prepaid expenses and other current assets	8,183	8,851
Total current assets	133,348	154,129
Property and equipment, net	12,594	12,173
Long-term prepaid fixed assets	157	199
Long-term deposits	1,351	0
Restricted cash	78	172
Total assets	147,528	166,673
Current liabilities:
Accounts payable	1,460	3,192
Amounts due to related parties	16,787	19,407
Accrued expense and other current liabilities	5,784	4,519
Notes payable	380	376
Total current liabilities	24,411	27,494
Other liabilities
Notes payable, net of current portion	10,226	10,323
Other long-term liabilities	236	237
Total liabilities	34,873	38,054
Preferred stock: $0.0001 par value,50,000,000 shares authorized at March 31, 2022 and December 31, 2021	0	0
Stockholders' Equity:
Additional paid-in capital	360,121	357,822
Accumulated deficit	(247,744)	(229,481)
Total stockholders equity (deficit)	112,655	128,619
Total liabilities, convertible preferred stock, and stockholders equity (deficit)	147,528	166,673
Class A Common Stock [Member]
Stockholders' Equity:
Common stock:	278	278
Common Class B [Member]
Stockholders' Equity:
Common stock:	$ 0	$ 0

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized/designated	50,000,000	50,000,000
Class A Common Stock [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	111,967,092	111,518,094
Common stock, shares outstanding	111,967,092	111,518,094
Common Class B [Member]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	13,874,132	13,874,132
Common stock, shares outstanding	13,874,132	13,874,132

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Consolidated Statements of Income [Abstract]
Revenue		$ 17
Cost of revenue		1
Gross (loss) profit		16
Operating expenses:
Research and development	$ 11,478	11,688
General and administrative	6,686	8,584
Total operating expenses	18,164	20,272
Loss from operations	(18,164)	(20,256)
Other (income) expense:
Interest expense, net	105	511
Interest income	5
Change in fair value of convertible notes		2,667
Change in fair value of simple agreements for future equity		8,365
Change in fair value of warrant liability		214
Loss on foreign currency translation, net	1	(8)
Other (income) expense	99	11,765
Loss before income taxes	(18,263)	(32,021)
Net loss	$ (18,263)	$ (32,021)
Net loss per share, basic and diluted	$ (0.15)	$ (0.47)
Weighted average common shares outstanding, basic and diluted	125,709,613	68,550,993

Condensed Consolidated Statements of Equity - USD ($) $ in Thousands	Total	Class A Common Stock [Member]	Class B Common Stock [Member]	Common Stock [Member] Class A Common Stock [Member]	Common Stock [Member] Class B Common Stock [Member]	Preferred Stock [Member]	Preferred Stock [Member] Series Seed Stock [Member]	Preferred Stock [Member] Series Seed-1 Stock [Member]	Preferred Stock [Member] Series Seed-2 Stock [Member]	Preferred Stock [Member] Series A-1 Stock [Member]	Preferred Stock [Member] Series A-2 Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] SAFEs [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Warrants [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Convertible Debt [Member]	Preferred Stock [Member] Series A Preferred Stock [Member] Notes Payable, Related Parties [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Treasury Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2020	$ (87,375)			$ 272		$ 62,475	$ 10,383	$ 20,903	$ 11,315	$ 4,640	$ 15,234	$ 0					$ 0	$ (23)	$ 4,682	$ (92,306)
Beginning balance, common shares at Dec. 31, 2020				60,360,523	10,999,149													3,169,093
Beginning balance, preferred shares at Dec. 31, 2020							7,831,528	22,876,457	14,615,399	1,871,511	6,307,690	0					0
Issuance of common stock upon exercise of stock options, shares				9,785
Issuance of common stock upon exercise of stock options	4																		4
Issuance of stock, shares				485,836													5,441,863
Issuance of stock	103																$ 43,480		103
Exhange of preferred stock, shares							(7,831,528)	(22,876,457)	(14,615,399)	(1,871,511)	(6,307,690)	53,502,585
Exchange of preferred stock							$ (10,383)	$ (20,903)	$ (11,315)	$ (4,640)	$ (15,234)	$ 62,475
Conversion of stock, shares													4,539,060	134,106	3,624,114	423,230
Conversion of stock													$ 35,600	$ 614	$ 27,545	$ 2,205
Vesting of restricted stock, shares				15,405
Retirement of treasury stock in merger, shares				(3,169,093)														3,169,093
Retirement of treasury stock in merger																		$ 23	(23)
Stock-based compensation expense	3,440																		3,440
Net loss	(32,021)																			(32,021)
Ending balance at Mar. 31, 2021	(115,849)			$ 272		$ 171,919	$ 0	$ 0	$ 0	$ 0	$ 0	$ 128,439					$ 43,480	$ 0	8,206	(124,327)
Ending balance, common shares at Mar. 31, 2021				57,702,456	10,999,149
Ending balance, preferred shares at Mar. 31, 2021							0	0	0	0	0	62,223,095					5,441,863
Ending balance, treasury shares at Mar. 31, 2021																		0
Beginning balance at Dec. 31, 2021	$ 128,619			$ 278															357,822	(229,481)
Beginning balance, common shares at Dec. 31, 2021		111,518,094	13,874,132	111,518,094	13,874,132
Issuance of common stock upon exercise of stock options, shares	842,938			448,998
Issuance of common stock upon exercise of stock options	$ 121																		121
Stock-based compensation expense	2,178																		2,178
Net loss	(18,263)																			(18,263)
Ending balance at Mar. 31, 2022	$ 112,655			$ 278															$ 360,121	$ (247,744)
Ending balance, common shares at Mar. 31, 2022		111,967,092	13,874,132	111,967,092	13,874,132

Condensed Consolidated Statements of Equity (Parenthetical)	Mar. 31, 2022 USD ($)
Preferred Stock [Member] \| Series B Preferred Stock [Member]
Issuance of stock, issuance costs	$ 55,000

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (18,263)	$ (32,021)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	333,000	282,000
Amortization of debt issuance costs	14	228
Change in fair value of Series A preferred stock	2,178	3,440
Change in fair value of convertible notes		2,667
Change in fair value of warrant liability		214
Change in fair value of simple agreements for future equity		8,365
Changes in operating assets and liabilities:
Accounts receivable		26
Amounts due to related parties	(6)	(5)
Prepaid expenses and other current assets	667	(12,752)
Long-term deposits	(1,351)
Deferred offering costs		(862)
Accounts payable	(1,733)	914
Amounts due to related parties	(2,620)	(1,671)
Accrued expenses and other current liabilities	1,268	2,937
Other liabilities	(1)	(3)
Net cash used in operating activities	(19,514)	(28,241)
Cash flows from investing activities:
Purchase of property and equipment	(713)
Net cash used in investing activities	(713)
Cash flows from financing activities:
Proceeds from issuance of convertible notes payable with related parties		2,000
Repayment of convertible notes		(2,000)
Repayments Of Related Party Debt	107	104
Proceeds from issuance of simple agreement for future equity		2,900
Proceeds from exercise of stock options	121	4
Net cash provided by financing activities	14	46,280
Increase in cash, cash equivalents, and restricted cash	(20,213)	18,039
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance	145,057	31,198	$ 31,198
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance	124,844	49,237
Supplemental Disclosure
Cash paid for interest	92	96
Noncash Financing Activities
Reitrement Of Treasury Shares	$ 23
Series B Preferred Stock [Member]
Proceeds from issuance of convertible preferred stock, net of issuance costs		43,480
Conversion Of Stock Amount Issued 1			$ 122,800
Simple Agreement for Future Equity [Member]
Conversion Of Stock Amount Issued 1		35,600
Series Seed, Series Seed-1, Series Seed-2, Series A-1 and Series A-2 for Series A [Member]
Conversion Of Stock Amount Issued 1		62,475
Convertible Notes Payable to Series A Preferred [Member]
Conversion Of Stock Amount Issued 1		$ 27,545

Nature of the Business	3 Months Ended
Nature of the Business	Mar. 31, 2022
Nature of the Business [Abstract]
Nature of the Business	1. Nature of the Business Vaxxinity, Inc., a Delaware corporation (“Vaxxinity ,” and together with its subsidiaries, the “Company”), was formed through the combination of two separate businesses that originated from United Biomedical, Inc. (“UBI”) in two separate transactions: a spin-out from UBI in 2014 of operations focused on developing chronic disease product candidates that resulted in United Neuroscience (“UNS”), and a second spin-out from UBI in 2020 of operations focused on the development of a COVID-19 vaccine that resulted in C19 Corp. (“COVAXX”). On February 2, 2021, Vaxxinity was incorporated for the purpose of reorganizing and combining UNS and COVAXX and on March 2, 2021, did so by acquiring all of the outstanding equity interests of UNS and COVAXX pursuant to a contribution and exchange agreement (the “Contribution and Exchange Agreement”) whereby the existing equity holders of UNS and COVAXX contributed their equity interests in each of UNS and COVAXX in exchange for equity in Vaxxinity (the “Reorganization”). The Company is a biotechnology company currently focused on developing product candidates for human use in the fields of neurology and coronaviruses utilizing its “Vaxxine Platform”—a peptide vaccine technology first developed by UBI and subsequently refined over the last two decades. The Company is engaged in the development and commercialization of rationally designed prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical need. UBI is a significant shareholder of the Company and, therefore, considered a related party. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing, and compliance with government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability. The Company’s product candidates are in development and will require significant additional research and development efforts, including extensive pre-clinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and is dependent upon the services of its employees and consultants. Contribution and Exchange Agreement On March 2, 2021, in accordance with the Contribution and Exchange Agreement, (i) all outstanding shares of UNS and COVAXX preferred stock and common stock were contributed to Vaxxinity and exchanged for like shares of stock in Vaxxinity, (ii) the outstanding options to purchase shares of UNS and COVAXX common stock were terminated and substituted with options to purchase shares of common stock in Vaxxinity, (iii) the outstanding warrant to purchase shares of COVAXX common stock was cancelled and exchanged for a warrant to acquire common stock in Vaxxinity and (iv) each outstanding Reorganization Convertible Note (as defined below) was contributed to Vaxxinity and the holders of such notes received Series A preferred stock in Vaxxinity. In particular: • Each UNS common share and convertible preferred share was exchanged for 0.2191 shares of Vaxxinity common stock or Series A preferred stock, as applicable; • Each share of COVAXX common and convertible preferred stock was exchanged for 3.4233 shares of Vaxxinity common stock or Series A preferred stock, as applicable (and prior to the closing of the Reorganization, all the holders of outstanding COVAXX SAFEs agreed to convert such SAFEs into shares of Series A-3 preferred stock of COVAXX, which shares were then exchanged for shares of Vaxxinity’s Series A preferred stock); • The Reorganization Convertible Notes were exchanged for an aggregate of 4,047,344 shares of Vaxxinity’s Series A preferred stock; and • Each outstanding option of both UNS and COVAXX to purchase common shares of UNS or COVAXX was terminated and substituted with an option to purchase shares of Class A common stock of Vaxxinity. Each outstanding UNS option was exchanged based on a conversion ratio of 0.2191 . Each outstanding COVAXX option was exchanged based on a conversion ratio of 3.4233 . All parties to the Contribution and Exchange Agreement intended that the contribution of outstanding equity interests to Vaxxinity in exchange for Vaxxinity’s common stock and preferred stock be treated as an integrated transaction for U.S. federal income tax purposes that is governed by Section 351(a) of the Internal Revenue Code of 1986, as amended. The Reorganization was determined to be a common control transaction, so the carrying values of all contributed assets and assumed liabilities remained unchanged and the financial information for all periods in the financial statements presented prior to the Reorganization are presented on a consolidated basis. Reverse Stock Split On October 29, 2021, the Company effectuated a reverse stock split of 1-for- 1.556 (the “Stock Split”) of the Company’s Class A and Class B common stock pursuant to an amendment to the Company’s Amended and Restated Certificate of Incorporation approved by the Company’s board of directors and stockholders. As a result of the Stock Split, the Company also adjusted the share and per share amounts associated with its options and warrants to purchase shares of its common stock. These unaudited condensed consolidated financial statements including the notes have been retroactively adjusted to reflect the Stock Split for all periods presented. Any fractional shares that would have resulted from the Stock Split have been rounded down to the nearest whole share. Initial Public Offering On November 15, 2021, the Company closed its IPO of 6,000,000 shares of Class A common stock at a public offering price of $ 13.00 per share. On November 18, 2021 the Company held a subsequent closing for the issuance of an additional 537,711 shares of Class A common stock pursuant to a 30-day option granted to the underwriters to purchase up to an additional 900,000 shares of Class A common stock at the IPO price, less underwriting discounts and commissions. The aggregate net proceeds to the Company from the offering, after deducting underwriting discounts and commissions and other offering expenses payable by the Company, was approximately $ 71.1 million. Upon the closing of the IPO, all previously outstanding shares of the Company’s redeemable convertible preferred stock were automatically converted at the same ratio used for the Stock Split (1-for- 1.556 ) into shares of its Class A common stock. Liquidity At three months ended March 31, 2022, the Company had $124.8 million of cash and cash equivalents. To date, the Company has primarily financed its operations through the sale of convertible preferred stock and common stock and borrowings under promissory notes (including Convertible Notes), a portion of which has been raised from related party entities. The Company has experienced significant negative cash flows from operations since inception, and incurred a net loss of $18.3 million for the three months ended March 31, 2022. Net cash used in operating activities for the three months ended March 31, 2022 was $19.5 million. In addition, as of March 31, 2022, the Company has an accumulated deficit of $247.7 million. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future. As of the date these financial statements were available to be issued, the Company expects its existing cash and cash equivalents to be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months. The Company will need to obtain additional funding beyond the period that is 12 months from the date these financial statements were available to be issued whether through collaboration agreements, private or public equity or debt offerings or a combination thereof, and such additional funding may not be available on terms the Company finds acceptable or at all. If the Company is unable to obtain sufficient capital to continue to advance its programs, the Company would be forced to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to third parties to develop and market product candidates that the Company would otherwise prefer to develop and market itself. The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of presentation The accompanying interim unaudited condensed consolidated financial statements have been prepared using generally accepted accounting principles in the United States of America (GAAP) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial reporting. The unaudited condensed consolidated financial statements for the periods presented include the accounts of UNS and COVAXX that were parties to the Contribution and Exchange Agreement. All share and per share amounts, as originally recorded by each entity, have been converted to a number of shares and per share amounts using the conversion ratios determined under the Contribution and Exchange Agreement and the Stock Split ratio. These interim condensed consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary to fairly present the results of the interim periods. The condensed consolidated balance sheet at December 31, 2021, has been derived from the audited financial statements at that date. Operating results for the three months ended March 31, 2022 and cash flows for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ended December 31, 2022 or any other future period. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been omitted in accordance with the rules and regulations for interim reporting of the SEC. These interim unaudited condensed financial statements should be read in conjunction with the financial statements and notes thereto included in our report for the year ended December 31, 2021. Leases At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating leases or financing leases. Operating leases are included in Operating lease right-of-use assets and Operating lease liabilities in our Condensed Consolidated Balance Sheets. Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. If a lease does not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. Right-of-use (ROU) assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Lease agreements with both lease and nonlease components, are generally accounted for together as a single lease component. Related party transactions The Company has a Related Party policy which defines related parties, and assigns oversight responsibility for related party transactions to the Company's Audit Committee. The Committee reviews in advance related party transactions, and considers multiple factors, including the proposed aggregate value of the transaction, or, in the case of indebtedness, the amount of principal that would be involved, the benefits to the Company of the proposed transaction, the availability of other sources of comparable products or services, and an assessment of whether the proposed transaction is on terms that are comparable to the terms available to or from, as the case may be, unrelated third parties. Under the policy, related party transactions are approved only if the Committee determines in good faith that the transaction is not inconsistent with the interests of the Company and its shareholders. Significant accounting policies The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements are disclosed in our annual financial statements for the year ended December 31, 2021. There have been no changes to the Company’s significant accounting policies during the three months ended March 31, 2022. Recently issued accounting pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. Recently adopted accounting standards In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”). ASU 2018-11 provided an alternative method in addition to the modified retrospective transition method for ASU No. 2016-02, Leases: Amendments to the FASB Accounting Standards Codification (“ASU 2016-02”), issued in February 2016. Under ASU 2018-11, an entity may elect to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Under ASU 2016-02, a lease is required to recognize assets and liabilities with lease terms of more than twelve months. ASU 2016-02 is effective for nonpublic business entities and public entities eligible to be Smaller Reporting Companies for fiscal years beginning after December 15, 2021. The Company adopted the new standard on January 1, 2022 using the modified retrospective approach. The Company has elected to apply the transition method that allows companies to continue applying the guidance under the lease standard in effect at that time in the comparative periods presented in the condensed financial statements and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit on the date of adoption. The Company has elected to combine lease components (for example fixed rent payments) with non-lease components (for example, common-area maintenance costs) on our facility, lab equipment and CRO embedded lease asset classes. The Company also elected the “package of practical expedients”, which permits the Company not to reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company also elected the short-term lease practical expedients allowed under the standard. Lastly, the Company did not elect the practical expedient allowing the use-of-hindsight which would require the Company to reassess the lease term of its leases based on all facts and circumstances through the effective date. Results for reporting period beginning after January 1, 2022 are presented under the new standard, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Upon adoption of the new lease standard, on January 1, 2022, the Company was not entered into any leases subject to ASC 842 and did not capitalize a ROU asset or lease liability.

Fair Value Measurements	3 Months Ended
Fair Value Measurements	Mar. 31, 2022
Fair Value Measurements [Abstract]
Fair Value Measurements	3. Fair Value Measurements The Company's money market accounts are shown at fair value based on unadjusted quoted market prices in active markets for identical assets. The following table presents information about the Company’s financial instruments measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values (in thousands): During the three months ended March 31, 2022 and the year ended December 31, 2021, there were no transfers between Level 1, Level 2 and Level 3. December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market account $ 139,794 $ — $ — $ 139,794 Total assets $ 139,794 $ — $ — $ 139,794 March 31, 2022 Level 1 Level 2 Level 3 Total Assets: Money market account $ 119,796 $ — $ — $ 119,796 Total assets $ 119,796 $ — $ — $ 119,796

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Prepaid Expenses and Other Current Assets	3 Months Ended
Prepaid Expenses and Other Current Assets	Mar. 31, 2022
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	4. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): March 31, December 31, 2022 2021 Prepaid materials and supplies $ 3,657 $ 3,517 Deposits 3,468 4,379 Clinical prepayments 709 614 Other 349 341 $ 8,183 $ 8,851 The Company’s prepaid material and supplies related to enzyme-linked immunosorbent assay (“ELISA”) test production, of which $ 1.0 million was paid to a related party and $ 2.5 million related to materials to be utilized during its Phase 3 COVID-19 vaccine clinical trial.

Property and Equipment	3 Months Ended
Property and Equipment	Mar. 31, 2022
Property and Equipment [Abstract]
Property and Equipment	5. Property and Equipment Property and equipment, net consisted of the following (in thousands): March 31, December 31, 2022 2021 Airplane $ 11,983 $ 11,983 Laboratory and computer equipment 2,560 1,831 Software 169 168 Facilities, furniture and fixtures 110 85 Vehicles 86 87 Total property and equipment 14,908 14,154 Less: accumulated depreciation (2,314) (1,981) Property and equipment, net $ 12,594 $ 12,173

Accrued Expenses and Other Current Liabilities	3 Months Ended
Accrued Expenses and Other Current Liabilities	Mar. 31, 2022
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	6. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): March 31, December 31, 2022 2021 Accrued external research and development $ 3,498 $ 1,501 Accrued bonuses 1,200 2,294 Accrued professional fees and other 1,055 692 Accrued interest 31 32 $ 5,784 $ 4,519

Other Long-Term Liabilities	3 Months Ended
Other Long-Term Liabilities	Mar. 31, 2022
Other Liabilities Disclosure [Abstract]
Other Long-Term Liabilities	7. Other Long-Term Liabilities Other long-term liabilities consisted of the following (in thousands): March 31, December 31, 2022 2021 Accrued tax provision 236 236 Accrued rent — 1 $ 236 $ 237 As of March 31, 2022 and December 31, 2021, approximately $ 0.2 million of the accrued tax provision relates to penalties and interest the Company may be subject to paying for late filing fees related to a foreign subsidiary. The Company expects these amounts to be forgiven but has accrued for them until the statute of limitations expires and it is appropriate to write them off.

Notes Payable	3 Months Ended
Notes Payable	Mar. 31, 2022
Notes payable with related parties [Abstract]
Notes payable with related parties [Text Block]	8. Notes Payable Notes Payable with Related Parties In December 2018, the Company entered into related party convertible notes payable (the “2018 Related Notes” and together with the Convertible Notes, the “Reorganization Convertible Notes”) for $ 2.0 million in aggregate proceeds, received in three tranches. The 2018 Related Notes bore simple interest at an annual rate of 5 % and contain a number of provisions addressing events of default and prepayment. In accordance with the Contribution and Exchange Agreement, on March 2, 2021, the 2018 Related Notes were converted into Series A preferred stock. During the three months ended March 31, 2021, the Company recognized interest expense of less than $ 0.1 million on the 2018 Related Notes. 2019 Executive Note In November 2019, the Company borrowed $ 0.1 million from its Chief Executive Officer (the “2019 Executive Note”). No formal loan agreement was executed. The Company has elected to accrue interest at an annual rate of 5 %, consistent with the terms and conditions of the Convertible Notes and 2018 Related Notes, which was the closest benchmark the Company could evaluate. The 2019 Executive Note was repaid in August 2021. The activity of the 2018 Related Notes and 2019 Executive Note is as follows (in thousands): Note Payable—Airplane In connection with the acquisition of an airplane, the Company entered into a note payable agreement (the “2025 Note”) in June 2020 for $ 11.5 million, with an annual interest rate of 3.4 % and a maturity date of June 9, 2025. Principal and interest payments are payable monthly in the amount of $ 0.07 million with a final payment of $ 9.4 million at maturity. The 2025 Note is guaranteed by the co-founders of the Company. In addition, the Company incurred debt issuance costs of $ 0.3 million, which are being amortized over the term of the loan. There are no financial covenants associated with the 2025 Note. The carrying value of the 2025 Note is as follows (in thousands): As of March 31, 2022, the remaining principal payments for the 2025 Note, are as follows (in thousands): Interest expense associated with the 2025 Note was $ 0.1 million for each of the three months ended March 31, 2022 and 2021. As of March 31, 2022, accrued interest of less than $ 0.1 million was included in accrued expenses and other liabilities in the accompanying condensed consolidated balance sheets as of March 31, 2022 (unaudited) and December 31, 2021. Note Payable—Paycheck Protection Program The Company applied for and received a loan, which is in the form of a note dated May 5, 2020, from HSBC Bank USA, National Association (“HSBC”) in the aggregate amount of approximately $ 0.3 million (the “PPP Loan”), pursuant to the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. As of March 31, 2021, there were no events of default under the PPP Loan. The Company paid off the PPP Loan in full, including all accrued but unpaid interest to the repayment date, in August 2021. 2018 Related Notes and 2019 Executive Note Related Party Principal Accrued Interest Balance December 31, 2020 $ 2,100 $ 194 $ 2,294 Accrued interest — 18 18 Conversion (2,000) (205) (2,205) March 31, 2021 $ 100 $ 7 $ 107 March 31, December 31, 2022 2021 Principal $ 10,776 $ 10,883 Unamortized debt issuance cost (170) (184) Carrying amount 10,606 10,699 Less: current portion (380) (376) Note payable, net of current portion and debt issuance cost $ 10,226 $ 10,323 Amount 2022 $ 322 2023 444 2024 458 2025 9,552 $ 10,776

Convertible Preferred Stock	3 Months Ended
Convertible Preferred Stock	Mar. 31, 2022
Convertible preferred stock [Abstract]
Convertible preferred stock	9. Convertible Preferred Stock In connection with the Reorganization, each UNS convertible preferred share was exchanged for 0.2191 shares of Vaxxinity preferred stock and each share of COVAXX convertible preferred stock was exchanged for 3.4233 shares of Vaxxinity preferred stock. During the first and second quarters of 2021, the Company raised gross proceeds of $ 122.8 million in connection with its Series B preferred stock financing. The Company issued a total of 15,365,574 shares at a price of $ 8.00 per share. All shares of the Company’s Series B preferred stock converted into shares of the Company’s Class A common stock concurrently with the closing of the initial public offering. As of March 31, 2022 and December 31, 2021, Vaxxinity’s Amended and Restated Certificate of Incorporation authorized 50,000,000 shares of preferred stock with a par value of $ 0.0001 per share. There were no shares of preferred stock outstanding as of March 31, 2022 and December 31, 2021.

Common Stock	3 Months Ended
Common Stock	Mar. 31, 2022
Common Stock [Abstract]
Common Stock	10. Common Stock As explained in Note 1, in accordance with the Contribution and Exchange Agreement, on March 2, 2021, all outstanding shares of common stock of UNS and COVAXX were contributed to Vaxxinity and exchanged for an aggregate of 60,360,523 shares of Vaxxinity’s Class A common stock and 10,999,149 shares of Vaxxinity’s Class B common stock. Each UNS share of common stock was exchanged for 0.2191 shares of Vaxxinity common stock and each share of COVAXX common stock was exchanged for 3.4233 shares of Vaxxinity common stock. As of March 31, 2022 and December 31, 2021, Vaxxinity’s Amended and Restated Certificate of Incorporation authorized 1,100,000,000 shares of common stock with a par value of $ 0.0001 per share, of which 1,000,000,000 shares have been designated as Class A common stock and 100,000,000 shares have been designated as Class B common stock. Holders of Class A common stock and Class B common stock have identical rights, except with respect to voting and conversion. Except as otherwise expressly provided in Vaxxinity’s Amended and Restated Certificate of Incorporation or Bylaws, or required by applicable law, holders of Class A common stock will be entitled to one vote per share on all matters submitted to a vote of stockholders and holders of our Class B common stock will be entitled to ten votes per share on all matters submitted to a vote of stockholders. Holders of Class A common stock and Class B common stock vote together as a single class on all matters submitted to a vote of stockholders, except (i) amendments to Vaxxinity’s Amended and Restated Certificate of Incorporation to increase or decrease the par value of a class of capital stock, in which case the applicable class would be required to vote separately to approve the proposed amendment and (ii) amendments to Vaxxinity’s Amended and Restated Certificate of Incorporation that alter or change the powers, preferences or special rights of a class of capital stock in a manner that affects its holders adversely, in which case the applicable class would be required to vote separately to approve the proposed amendment. Holders of common stock are entitled to receive, ratably, dividends as may be declared by Vaxxinity’s board of directors out of funds legally available therefor if the board of directors, in its discretion, determines to issue dividends. The voting, dividend, and liquidation rights of the holders of common stock are subject to and qualified by the rights, powers, and preferences of the holders of Vaxxinity’s preferred stock. The Company has reserved shares of common stock for issuance for the following purposes: March 31, December 31, 2022 2021 Options issued and outstanding 20,274,077 21,387,909 Options available for future grants 6,727,691 7,209,538 Warrants issued and outstanding 1,928,020 1,928,020 28,929,788 30,525,467

Stock-Based Compensation	3 Months Ended
Stock-Based Compensation	Mar. 31, 2022
Stock-Based Compensation [Abstract]
Stock-Based Compensation	11. Stock-Based Compensation Stock Options As of March 31, 2022 there were options for 13,911,622 shares of Class A stock outstanding and options for 6,362,455 shares of Class B stock outstanding, of which 8,466,456 Class A and 4,897,414 Class B shares were exercisable, respectively. As of March 31, 2022, the maximum number of stock options awards available for future issuance under the Company’s plans is 6,727,691 . The following table summarizes stock option activity during the three months ended March 31, 2022: The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the common stock for those options that had exercise prices lower than the fair value of the common stock as of March 31, 2022. The intrinsic value of options exercised during the three months ended March 31, 2022 was $ 3.6 million. The weighted-average grant-date fair value per share of options granted during the three months ended March 31, 2022 was $ 4.02 . Restricted Stock The following table summarizes the Company’s restricted stock activity for the three months ended March 31, 2022: Stock-based compensation expense recognized on vested restricted stock was immaterial for the three months ended March 31, 2022. Stock-Based Compensation Expense The Company recorded stock-based compensation expense in the following expense categories in the accompanying unaudited condensed consolidated statements of operations (in thousands): As of March 31, 2022, total unrecognized compensation cost related to the unvested stock-based awards was $ 24.2 million, which is expected to be recognized over a weighted average period of 3.0 years. Number of Stock Options Outstanding Weighted Price Per Share Weighted Contractual Term (years) Aggregate Intrinsic Value (in thousands) Balance at December 31, 2021 21,387,909 $ 5.25 7.4 $ 49,684 Granted 303,086 5.36 Exercised (842,938) (3.89) Forfeited (573,980) (5.16) Balance at March 31, 2022 20,274,077 $ 5.31 7.5 $ 32,167 Options vested and exercisable at March 31, 2022 13,363,870 $ 4.46 7.1 $ 27,022 Number of Shares Weighted Average Grant Date Fair Value Per Share Unvested at December 31, 2021 — $ — Issued 300,000 3.76 Unvested at March 31, 2022 300,000 $ 3.76

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2022
Income Taxes [Abstract]
Income Taxes	12. Income Taxes The Company computes its expected annual effective income tax rate in accordance with ASC 740 and makes changes on a quarterly basis, as necessary, based on certain factors such as changes in forecasted annual pre-tax income; changes to actual or forecasted permanent book to tax differences; impacts from tax audits with state, federal or foreign tax authorities; impacts from tax law changes; or change in judgment as to the realizability of deferred tax assets. The Company identifies items which are unusual and non-recurring in nature and treats these as discrete events. The tax effect of discrete items is recorded in the quarter in which the discrete events occur. The Company’s effective tax rate for the three months ended March 31, 2022 and 2021 was 0.00 %, due primarily to its uncertainty of realizing a benefit from net operating losses incurred during the period. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some or all of the recorded deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent on the generation of future taxable income in the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on these items and the consecutive years of pretax losses (resulting from impairment), management determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance for all taxing jurisdictions. The Company files income tax returns in the U.S. federal and various state and local jurisdictions. The Company also files returns in numerous foreign jurisdictions that have varied years remaining open for examination, but generally the statute of limitations is three to four years from when the return is filed. As of March 31, 2022, the Company currently has no ongoing audits. The Company has US net operating loss (“NOL”) carryforwards for federal and state income tax purposes. Use of the NOL carryforwards is limited under Section 382 of the Internal Revenue Code, as we have had a change in ownership of more than 50% of our capital stock over a three-year period as measured under Section 382 of the Internal Revenue Code. These complex changes of ownership rules generally focus on ownership changes involving shareholders owning directly or indirectly 5% or more of our stock, including certain public “groups” of shareholders as set forth under Section 382 of the Internal Revenue Code, including those arising from new stock issuances and other equity transactions. Some of these NOL carryforwards will expire if they are not used within certain periods. At this time, we consider it more likely than not that we will not have sufficient taxable income in the future that will allow us to realize these NOL carryforwards.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Net Loss Per Share	3 Months Ended
Net Loss Per Share	Mar. 31, 2022
Net Loss Per Share [Abstract]
Net Loss Per Share	13. Net Loss Per Share The Company’s unvested restricted common shares have been excluded from the computation of basic net loss per share. The Company’s potentially dilutive securities, which include options, unvested restricted stock, convertible notes payable and convertible preferred stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share as of March 31, 2022 and March 31, 2021 because including them would have had an anti-dilutive effect: March 31, March 31, 2022 2021 Options and RSUs issued and outstanding 20,574,077 19,712,504 Warrants issued and outstanding stock 1,928,020 128,702 22,502,097 19,841,206

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	14. Commitments and Contingencies Contractual Obligations The Company enters into agreements with contract research organizations (“CROs”) to conduct clinical trials and preclinical studies and contract manufacturing organizations (“CMOs”) to produce vaccines and other potential product candidates. Contracts with CROs and CMOs are generally cancellable, with notice, at the Company’s option. As of March 31, 2022, the Company had remaining prepayments to CROs of $ 3.1 million and remaining prepayments to CMOs of $ 2.6 million for activities associated with the conduct of its clinical trials and for the production of the Company’s anticipated vaccine product candidate. Michael J. Fox Foundation Grant On November 3, 2021, the Company was awarded a grant from the Michael J. Fox Foundation for Parkinson’s Research (“MJFF”) in the amount of $ 0.8 million to be used in a project for the exploration of markers for target engagement in individuals immunized with UB-312, an active a -Synuclein immunotherapy. The Company will oversee sample management, sample preparation (IgG fractions) and distribution, as well as characterize the binding properties of the antibodies against pathological forms of aSyn. As funding is expected to be utilized over a two-year period, as cash is received, the amount expected to the utilized within twelve months is recognized to short-term restricted cash/deposits, with a corresponding short-term accrued liability, which is released as the related expenses are offset. The Company recognizes payments from MJFF as a reduction of research and development expenses, in the same period as the expenses that the grant is intended to reimburse are incurred. The remaining balance of cash received is recognized to long-term restricted cash/deposits, with a corresponding long-term accrued liability. As of March 31, 2022, the balance of short-term restricted cash/deposits and the corresponding short-term accrued liability was $ 0 and the balance of long-term restricted cash/deposits and the corresponding long-term accrued liability was $ 0 . For the three months ended March 31, 2022, the Company did not recognize any reduction of research and development expenses for amounts reimbursed through the grant. Lease Agreements The Company has short-term leases resulting in $ 0.1 million short-term lease expense and less than $ 0.1 million variable lease expense during the three months ended March 31, 2022. As of March 31, 2022, the Company has not entered into any finance lease agreements or operating lease agreements resulting in the capitalization of a ROU asset or lease liability. License Agreements In August 2021, Vaxxinity entered into a license agreement (the “Platform License Agreement”) with UBI and certain of its affiliates that expanded intellectual property rights previously licensed under previously issued license agreements with UBI. As part of the agreement, Vaxxini ty obtained a worldwide, sublicensable (subject to certain conditions), perpetual, fully paid-up, royalty-free license to research, develop, make, have made, utilize, import, export, market, distribute, offer for sale, sell, have sold, commercialize or otherwise exploit peptide-based vaccines in the field of all human prophylactic and therapeutic uses, except for such vaccines related to human immunodeficiency virus (HIV), herpes simplex virus (HSE) and Immunoglobulin E (IgE). The patents and patent applications licensed under the Platform License Agreement include claims directed to a CpG delivery system, artificial T helper cell epitopes and certain designer peptides and proteins utilized in UB-612. As described above, in consideration for the Platform License Agreement, the Company issued to UBI a warrant to purchase Class A common stock (the “UBI Warrant”). The Company considered ASC 805, “Business Combinations” (“ASC 805”) and ASC 730, “Research and Development” (“ASC 730”) in determining how to account for the issuance of the Class A common stock warrants. The Class A common stock warrants were issued to a related party in exchange for a license agreement. The majority of the voting interests in the related party and that of the Company were held by a group of immediate family members, at the time of the transaction, and as such the transaction constitutes a common control transaction, which requires the license to be accounted for at the carrying value in the books of the transferor. As the related party did not have any basis in the assets licensed, there was no accounting impact for the Company. Indemnification Agreements In the ordinary course of business, the Company may provide indemnification of varying scope and terms to employees, consultants, vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations, or cash flows, and it has not accrued any liabilities related to such obligations as of March 31, 2022 and December 31, 2021. Legal Proceedings From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. As of March 31, 2022 and December 31, 2021, the Company was not a party to any material legal matters or claims.

Benefit Plans	3 Months Ended
Benefit Plans	Mar. 31, 2022
Benefit Plans [Abstract]
Benefit Plans	15. Benefit Plans In March 2018, the Company established a defined contribution savings plan under Section 401(k) of the Code. This plan covers substantially all U.S. employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. The Company does not make matching contributions to the Plan. The Company offers its Ireland-based employees a Personal Retirement Savings Account (“PRSA”) that allows participants to defer a portion of their annual compensation. The Company provides contributions equal to 4 % of each participant’s annual salary. During both of the three months ended March 31, 2022 and 2021, the Company contributed less than $ 0.1 million to PRSA accounts.

Related Party Transactions	3 Months Ended
Related Party Transactions	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	16. Related Party Transactions The Company has related party arrangements with UBI and a number of its affiliated companies listed namely, United Biomedical, Inc., Asia (“UBI-Asia”), UBI Pharma, Inc. (“UBI-P”), United BioPharma, Inc (“UBP”) and UBI IP Holding (“UBI-IP”). As of March 31, 2022 UBI owned 44 % of the Company’s stock. The majority of the voting interests in both UBI and the Company were held by a group of immediate family members, and as such the entities are under common control. Total amounts due to related parties were $ 16.8 million and $ 19.4 million as of March 31, 2022 and December 31, 2021, respectively. Total amounts due from related parties were $ 0.4 million and $ 0.4 million as of March 31, 2022 and December 31, 2021, respectively. Total service fees incurred were $ 0.8 million and $ 8.7 million for the three months ended March 31, 2022 and 2021, respectively. Taiwan Centers for Disease Control Grant (“Taiwan CDC”) UBI-Asia, which is responsible for applying for and managing grants on our behalf under the COVID-19 program, was awarded a grant by the Taiwan CDC for COVID-19 vaccine development. The Company contracted with UBI-Asia to conduct a two-phase study of a COVID-19 vaccine clinical trial in Taiwan. The grant provides that costs incurred to complete the two phases of the clinical trial will be reimbursed based on the achievement of certain milestones as provided in the agreement. The Company provides administrative services to UBI-IP. Under the arrangement, the Company issues vendor payments and provides technical services mostly for legal services on behalf UBI-IP. The Company bills UBI-IP for services based on the costs incurred with no markup. Total related party operating activity, including the activity described above, are as follows (in thousands): March 31, December 31, 2022 2021 Consolidated balance sheet Assets Prepaid expenses and other current assets $ 3,546 $ 3,517 Amounts due from related parties 399 393 Property and equipment, net 299 337 Liabilities Amounts due to related parties 16,787 19,407 Accrued expenses 168 — Three Months Ended March 31, 2022 2021 Operating expenses Research and development Services provided by related parties 784 10,633 Taiwan CDC grant reimbursement from related party — (2,417) General and administrative Services provided by related parties — 507

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events The Company has evaluated subsequent events and has concluded that no events or transactions have occurred that require disclosure in the accompanying consolidated financial statements, except as follows: Coalition for Epidemic Preparedness Innovations (“CEPI”) Grant In April 2022, the Company entered into an agreement with the Coalition for Epidemic Preparedness Innovations (“CEPI”) whereby CEPI has agreed to provide funding of up to US$ 9.25 million to co-fund a Phase 3 clinical trial of Vaxxinity’s next generation UB-612 COVID-19 vaccine candidate as a heterologous – or ‘mix-and-match’ – booster dose. The Phase 3 trial, which began in the US earlier this year, is evaluating the ability of UB-612 to boost COVID-19 immunity against the original strain and multiple variants of concern including Omicron - in people aged 16 years or older, who have been previously immunized with an authorized COVID-19 vaccine. The Company will also be performing further manufacturing scale-up work to enable readiness for a pivotal trial and potential commercialization. If successful, a portion of the released doses of the commercial product will be delivered to the COVID-19 Vaccines Global Access (“COVAX”) consortium for distribution to developing countries at low cost. Lease In April 2022, the Company entered into a facility lease agreement for an additional 4,419 square feet of space in New York, New York. The lease is estimated to commence in April 2022 and expire March 2029 with no option to renew. The lease will be recognized and measured in accordance with ASC 842 guidance.

Summary of Significant Accounting Policies (Policy)	3 Months Ended
Summary of Significant Accounting Policies (Policy)	Mar. 31, 2022
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation The accompanying interim unaudited condensed consolidated financial statements have been prepared using generally accepted accounting principles in the United States of America (GAAP) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial reporting. The unaudited condensed consolidated financial statements for the periods presented include the accounts of UNS and COVAXX that were parties to the Contribution and Exchange Agreement. All share and per share amounts, as originally recorded by each entity, have been converted to a number of shares and per share amounts using the conversion ratios determined under the Contribution and Exchange Agreement and the Stock Split ratio. These interim condensed consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary to fairly present the results of the interim periods. The condensed consolidated balance sheet at December 31, 2021, has been derived from the audited financial statements at that date. Operating results for the three months ended March 31, 2022 and cash flows for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the fiscal year ended December 31, 2022 or any other future period. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been omitted in accordance with the rules and regulations for interim reporting of the SEC. These interim unaudited condensed financial statements should be read in conjunction with the financial statements and notes thereto included in our report for the year ended December 31, 2021.
Foreign currency translation	Significant accounting policies The significant accounting policies used in preparation of these unaudited condensed consolidated financial statements are disclosed in our annual financial statements for the year ended December 31, 2021. There have been no changes to the Company’s significant accounting policies during the three months ended March 31, 2022.
Recently Adopted and Issued Accounting Pronouncements	Recently issued accounting pronouncements From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. Recently adopted accounting standards In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”). ASU 2018-11 provided an alternative method in addition to the modified retrospective transition method for ASU No. 2016-02, Leases: Amendments to the FASB Accounting Standards Codification (“ASU 2016-02”), issued in February 2016. Under ASU 2018-11, an entity may elect to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Under ASU 2016-02, a lease is required to recognize assets and liabilities with lease terms of more than twelve months. ASU 2016-02 is effective for nonpublic business entities and public entities eligible to be Smaller Reporting Companies for fiscal years beginning after December 15, 2021. The Company adopted the new standard on January 1, 2022 using the modified retrospective approach. The Company has elected to apply the transition method that allows companies to continue applying the guidance under the lease standard in effect at that time in the comparative periods presented in the condensed financial statements and recognize a cumulative-effect adjustment to the opening balance of accumulated deficit on the date of adoption. The Company has elected to combine lease components (for example fixed rent payments) with non-lease components (for example, common-area maintenance costs) on our facility, lab equipment and CRO embedded lease asset classes. The Company also elected the “package of practical expedients”, which permits the Company not to reassess under the new standard the Company’s prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company also elected the short-term lease practical expedients allowed under the standard. Lastly, the Company did not elect the practical expedient allowing the use-of-hindsight which would require the Company to reassess the lease term of its leases based on all facts and circumstances through the effective date. Results for reporting period beginning after January 1, 2022 are presented under the new standard, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Upon adoption of the new lease standard, on January 1, 2022, the Company was not entered into any leases subject to ASC 842 and did not capitalize a ROU asset or lease liability.
Lessee Leases [Policy Text Block]	Leases At inception of a contract, we determine whether an arrangement is or contains a lease. For all leases, we determine the classification as either operating leases or financing leases. Operating leases are included in Operating lease right-of-use assets and Operating lease liabilities in our Condensed Consolidated Balance Sheets. Lease recognition occurs at the commencement date and lease liability amounts are based on the present value of lease payments over the lease term. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. If a lease does not provide information to determine an implicit interest rate, we use our incremental borrowing rate in determining the present value of lease payments. Right-of-use (ROU) assets represent our right to use an underlying asset for the lease term, and lease liabilities represent our obligation to make lease payments under the lease. ROU assets also include any lease payments made prior to the commencement date and exclude lease incentives received. Operating lease expense is recognized on a straight-line basis over the lease term. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Lease agreements with both lease and nonlease components, are generally accounted for together as a single lease component.
Related Party Transactions [Policy Text Block]	Related party transactions The Company has a Related Party policy which defines related parties, and assigns oversight responsibility for related party transactions to the Company's Audit Committee. The Committee reviews in advance related party transactions, and considers multiple factors, including the proposed aggregate value of the transaction, or, in the case of indebtedness, the amount of principal that would be involved, the benefits to the Company of the proposed transaction, the availability of other sources of comparable products or services, and an assessment of whether the proposed transaction is on terms that are comparable to the terms available to or from, as the case may be, unrelated third parties. Under the policy, related party transactions are approved only if the Committee determines in good faith that the transaction is not inconsistent with the interests of the Company and its shareholders.

Fair Value Measurements (Tables)	3 Months Ended
Fair Value Measurements (Tables)	Mar. 31, 2022
Fair Value Measurements [Abstract]
Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis	December 31, 2021 Level 1 Level 2 Level 3 Total Assets: Money market account $ 139,794 $ — $ — $ 139,794 Total assets $ 139,794 $ — $ — $ 139,794 March 31, 2022 Level 1 Level 2 Level 3 Total Assets: Money market account $ 119,796 $ — $ — $ 119,796 Total assets $ 119,796 $ — $ — $ 119,796

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
Prepaid Expenses and Other Current Assets (Tables)	Mar. 31, 2022
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	March 31, December 31, 2022 2021 Prepaid materials and supplies $ 3,657 $ 3,517 Deposits 3,468 4,379 Clinical prepayments 709 614 Other 349 341 $ 8,183 $ 8,851

Property and Equipment (Tables)	3 Months Ended
Property and Equipment (Tables)	Mar. 31, 2022
Property and Equipment [Abstract]
Property and Equipment, Net	March 31, December 31, 2022 2021 Airplane $ 11,983 $ 11,983 Laboratory and computer equipment 2,560 1,831 Software 169 168 Facilities, furniture and fixtures 110 85 Vehicles 86 87 Total property and equipment 14,908 14,154 Less: accumulated depreciation (2,314) (1,981) Property and equipment, net $ 12,594 $ 12,173

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
Accrued Expenses and Other Current Liabilities (Tables)	Mar. 31, 2022
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued expenses and other current liabilities	March 31, December 31, 2022 2021 Accrued external research and development $ 3,498 $ 1,501 Accrued bonuses 1,200 2,294 Accrued professional fees and other 1,055 692 Accrued interest 31 32 $ 5,784 $ 4,519

Other Long-Term Liabilities (Tables)	3 Months Ended
Other Long-Term Liabilities (Tables)	Mar. 31, 2022
Other Liabilities Disclosure [Abstract]
Other Liabilities	March 31, December 31, 2022 2021 Accrued tax provision 236 236 Accrued rent — 1 $ 236 $ 237

Notes payable (Tables)	3 Months Ended
Notes payable (Tables)	Mar. 31, 2022
Notes payable with related parties [Abstract]
Activity of the notes payable with related parties	2018 Related Notes and 2019 Executive Note Related Party Principal Accrued Interest Balance December 31, 2020 $ 2,100 $ 194 $ 2,294 Accrued interest — 18 18 Conversion (2,000) (205) (2,205) March 31, 2021 $ 100 $ 7 $ 107
Schedule of Maturities of Notes Payable	Amount 2022 $ 322 2023 444 2024 458 2025 9,552 $ 10,776
Schedule Of Carrying Values And Estimated Fair Values Of Debt Instruments [Table Text Block]	March 31, December 31, 2022 2021 Principal $ 10,776 $ 10,883 Unamortized debt issuance cost (170) (184) Carrying amount 10,606 10,699 Less: current portion (380) (376) Note payable, net of current portion and debt issuance cost $ 10,226 $ 10,323

Common Stock (Tables)	3 Months Ended
Common Stock (Tables)	Mar. 31, 2022
Common Stock [Abstract]
Reserved Shares of Common Stock for Issuance	March 31, December 31, 2022 2021 Options issued and outstanding 20,274,077 21,387,909 Options available for future grants 6,727,691 7,209,538 Warrants issued and outstanding 1,928,020 1,928,020 28,929,788 30,525,467

Stock-Based Compensation (Tables)	3 Months Ended
Stock-Based Compensation (Tables)	Mar. 31, 2022
Stock-Based Compensation [Abstract]
Summary of Stock Option Activity	Number of Stock Options Outstanding Weighted Price Per Share Weighted Contractual Term (years) Aggregate Intrinsic Value (in thousands) Balance at December 31, 2021 21,387,909 $ 5.25 7.4 $ 49,684 Granted 303,086 5.36 Exercised (842,938) (3.89) Forfeited (573,980) (5.16) Balance at March 31, 2022 20,274,077 $ 5.31 7.5 $ 32,167 Options vested and exercisable at March 31, 2022 13,363,870 $ 4.46 7.1 $ 27,022
Summary of Restricted Stock Activity	Number of Shares Weighted Average Grant Date Fair Value Per Share Unvested at December 31, 2021 — $ — Issued 300,000 3.76 Unvested at March 31, 2022 300,000 $ 3.76
Schedule of Stock-Based Compensation Expense for Stock Options	Three Months Ended March 31, 2022 2021 General and administrative $ 1,371 $ 3,167 Research and development 807 273 Total stock-based compensation expense $ 2,178 $ 3,440

Net Loss Per Share (Tables)	3 Months Ended
Net Loss Per Share (Tables)	Mar. 31, 2022
Net Loss Per Share [Abstract]
Schedule of Excluded Potential Common Shares from Computation of Diluted Net Loss Per Share	March 31, March 31, 2022 2021 Options and RSUs issued and outstanding 20,574,077 19,712,504 Warrants issued and outstanding stock 1,928,020 128,702 22,502,097 19,841,206

Related Party Transactions (Tables)	3 Months Ended
Related Party Transactions (Tables)	Mar. 31, 2022
Related Party Transactions [Abstract]
Schedule of Related Party Operating Activity	March 31, December 31, 2022 2021 Consolidated balance sheet Assets Prepaid expenses and other current assets $ 3,546 $ 3,517 Amounts due from related parties 399 393 Property and equipment, net 299 337 Liabilities Amounts due to related parties 16,787 19,407 Accrued expenses 168 — Three Months Ended March 31, 2022 2021 Operating expenses Research and development Services provided by related parties 784 10,633 Taiwan CDC grant reimbursement from related party — (2,417) General and administrative Services provided by related parties — 507

Nature of the Business (Narrative) (Details) $ / shares in Units, $ in Thousands				3 Months Ended
	Nov. 18, 2021 $ / shares shares	Nov. 15, 2021 $ / shares shares	Oct. 29, 2021	Mar. 31, 2022 USD ($) shares	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($) shares
Nature of Business Disclosures [Line Items]
Proceeds from issuance of simple agreement for future equity					$ 2,900
Proceeds from issuance of convertible notes payable with related parties					2,000
Repayment of convertible notes					2,000
Cash and cash equivalents				$ 124,766		$ 144,885
Net Income Loss				(18,263)	$ (32,021)
Accumulated deficit				$ (247,744)		$ (229,481)
Reverse stock split	1.556		1.556
Class A Common Stock [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares \| shares		6,000,000
Share Price \| $ / shares		$ 13.00
Underwriters [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares \| shares	900,000
Underwriters [Member] \| Class A Common Stock [Member]
Nature of Business Disclosures [Line Items]
Issuance of stock, shares \| shares	537,711
Share Price \| $ / shares	$ 71.1
UNS. [Member]
Nature of Business Disclosures [Line Items]
Note conversion ratio				3.4233
COVAXX [Member]
Nature of Business Disclosures [Line Items]
Note conversion ratio				0.2191
ConvertiblePreferredStockSharesIssuedUponConversion \| shares						3.4233
Debt Conversion Converted Instrument Shares Issued 1 \| shares				4,047,344

Fair Value Measurements (Narrative) (Details)	Mar. 31, 2022 USD ($)
Class Of Warrant Or Right [Line Items]
Fair value asset transfers, level 1 to level 2	$ 0
Fair value asset transfers, level 2 to level 1	0
Fair value liability transfers, level 1 to level 2	0
Fair value liability transfers, level 2 to level 1	$ 0

Fair Value Measurements (Schedule of Financial Instruments Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 124,766	$ 144,885
Assets	119,796	139,794
Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	119,796	139,794
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	119,796	139,794
Level 1 [Member] \| Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	$ 119,796	$ 139,794

Prepaid Expenses and Other Current Assets (Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Prepaid Expenses and Other Current Assets [Line Items]
Supplies	$ 3,657	$ 3,517
Related Party [Member]
Prepaid Expenses and Other Current Assets [Line Items]
Supplies	1,000
Vaccine Development [Member]
Prepaid Expenses and Other Current Assets [Line Items]
Supplies	$ 2,500

Prepaid Expenses and Other Current Assets (Prepaid Expenses and Other Current Assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid materials and supplies	$ 3,657	$ 3,517
Deposits	3,468	4,379
Clinical prepayments	709	614
Other	349	341
Total	$ 8,183	$ 8,851

Property and Equipment (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 0.3	$ 0.3

Property and Equipment (Property and Equipment, Net) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment	$ 14,908	$ 14,154
Less accumulated depreciation	(2,314)	(1,981)
Property and equipment, net	12,594	12,173
Air Transportation Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	11,983	11,983
Laboratory And Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	2,560	1,831
Software And Software Development Costs [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	169,000	168,000
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	86,000	87,000
Furniture And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 110	$ 85

Accrued Expenses and Other Current Liabilities (Accrued Expenses and Other Current Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Accrued Expenses and Other Current Liabilities [Abstract]
Accrued payroll and benefits	$ 3,498	$ 1,501
Accrued External Research And Development	1,200	2,294
Accrued professional fees and other	1,055	692
Accrued interest	31	32
Total	$ 5,784	$ 4,519

Other Long-Term Liabilities (Narrative) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Accrued Payroll Taxes Current And Noncurrent	$ 0.2	$ 0.2

Other Long-Term Liabilities (Other Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Accrued tax provision	$ 236	$ 236
Lease liability		1
Total	$ 236	$ 237

Notes payable (Notes payable with related parties) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Debt Instrument [Line Items]
Repayment	$ (107)	$ (104)
Additions	(6)	(5)
2019 Related Notes and 2020 Executive Note [Member]
Debt Instrument [Line Items]
Beginning balance		2,294
Debt Instrument Increase Accrued Interest	18
Conversion	(2,205)
Ending balance	107
2019 Related Notes and 2020 Executive Note [Member] \| Principal Amount [Member]
Debt Instrument [Line Items]
Beginning balance		2,100
Conversion	(2,000)
Ending balance	100
2019 Related Notes and 2020 Executive Note [Member] \| Accrued Interest [Member]
Debt Instrument [Line Items]
Beginning balance		$ 194
Debt Instrument Increase Accrued Interest	18
Conversion	(205)
Ending balance	$ 7

Notes payable (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2020	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Proceeds from issuance of convertible notes payable with related parties		$ 2,000
2018 Related Notes and Reorg. Convertible Notes [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties					$ 2,000
Debt Instrument Interest Rate Stated Percentage					5.00%
Interest Expense, Debt	$ 100	100
2019 Executive Note [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties				$ 100
Debt Instrument Interest Rate Stated Percentage				5.00%
Notes Payable, Airplane [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties			$ 11,500
Debt Instrument Interest Rate Stated Percentage			3.40%
Interest Expense, Debt	100	$ 100
Debt Instrument Periodic Payment Interest	70
Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid	9,400
Payments Of Debt Issuance Costs	300
Debt Instrument Increase Accrued Interest	100
Paycheck Protection Program [Member]
Debt Instrument [Line Items]
Notes Payable, Related Parties	$ 300

Notes payable (Carrying Value) (Details) - Note, 2025 [Member] - Notes Payable [Member] - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Principal	$ 10,776	$ 10,883
Unamortized debt issuance cost	170	184
Total	10,606	10,699
Less: current portion	(380)	(376)
Note payable, net of current portion and debt issuance cost	$ 10,226	$ 10,323

- Definition

Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.

+ References + Details

Notes payable (Annual Principal Payments) (Details) - Note, 2025 [Member] - Notes Payable [Member] - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
2021	$ 322
2022	444
2023	458
2024	9,552
Total	$ 10,776	$ 10,883

Convertible Preferred Stock (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2021	Mar. 31, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Preferred stock, par value		$ 0.0001	$ 0.0001
Preferred stock, shares authorized/designated		50,000,000	50,000,000
Series B Preferred Stock [Member]
Class Of Stock [Line Items]
Conversion Of Stock, Per Share	$ 8.00
Conversion Of Stock Amount Issued 1	$ 122.8
Conversion Of Stock Shares Issued 1	15,365,574
Convertible Preferred Shares [Member] \| UNS [Member]
Class Of Stock [Line Items]
Conversion Of Stock, Per Share	$ 0.2191
Convertible Preferred Shares [Member] \| COVAXX [Member]
Class Of Stock [Line Items]
Conversion Of Stock, Per Share	$ 3.4233

Common Stock (Narrative) (Details) - $ / shares		3 Months Ended
Common Stock (Narrative) (Details) - $ / shares	Nov. 15, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Class A Common Stock [Member]
Class Of Stock [Line Items]
Issuance of stock, shares	6,000,000
Share Price	$ 13.00
Common stock, shares authorized		1,000,000,000		1,000,000,000
Common stock, par value		$ 0.0001		$ 0.0001
Common Class B [Member]
Class Of Stock [Line Items]
Common stock, shares authorized		100,000,000		100,000,000
Common stock, par value		$ 0.0001		$ 0.0001
Common Stock [Member] \| Class A Common Stock [Member]
Class Of Stock [Line Items]
Issuance of stock, shares			485,836
Amended And Restated Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized		1,100,000,000		1,100,000,000
Common stock, par value		$ 0.0001		$ 0.0001
Amended And Restated Common Stock [Member] \| Class A Common Stock [Member]
Class Of Stock [Line Items]
Common stock, shares authorized		1,000,000,000		1,000,000,000
Amended And Restated Common Stock [Member] \| Common Class B [Member]
Class Of Stock [Line Items]
Common stock, shares authorized		100,000,000		100,000,000
UNS [Member] \| Class A Common Stock [Member]
Class Of Stock [Line Items]
Issuance of stock, shares		60,360,523
Shares converted		0.2191
UNS [Member] \| Common Class B [Member]
Class Of Stock [Line Items]
Issuance of stock, shares		10,999,149
Shares converted		3.4233

Common Stock (Reserved Share of Common Stock for Issuance) (Details) - shares	Mar. 31, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Options issued and outstanding	20,274,077	21,387,909
Options [Member]
Class Of Stock [Line Items]
Options issued and outstanding		21,387,909
Options available for future grants		7,209,538
Warrants issued and outstanding to purchase shares of common stock		1,928,020
Reserved Shares of Common Stock		30,525,467
Series Seed Preferred [Member] \| Options [Member]
Class Of Stock [Line Items]
Options issued and outstanding	20,274,077
Options available for future grants	6,727,691
Warrants issued and outstanding to purchase shares of common stock	1,928,020
Reserved Shares of Common Stock	28,929,788

Stock-Based Compensation (Narrative) (Details - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding	20,274,077		21,387,909
Options exercisable	13,363,870
Total stock-based compensation expense	$ 2,178	$ 3,440
Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant			7,209,538
Options outstanding			21,387,909
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted-average grant-date fair value per share of options granted	$ 3.76
2021 Stock Option and Grant Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized compensation cost	$ 24,200
Recognized over a weighted average period	3 years
2021 Stock Option and Grant Plan [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares available for grant	6,727,691
Intrincic value of options exercised	$ 3,600
Weighted-average grant-date fair value per share of options granted	$ 4.02
2021 Stock Option and Grant Plan [Member] \| Class A Common Stock [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding	13,911,622
Options exercisable	8,466,456
2021 Stock Option and Grant Plan [Member] \| Common Class B [Member] \| Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding	6,362,455
Options exercisable	4,897,414

Stock-Based Compensation (Summary of Stock Option Activity) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Stock-Based Compensation [Abstract]
Number of stock options, outstanding	21,387,909
Number of stock options, Granted	303,086
Number of stock options, Exercised	(842,938)
Number of stock options, Forfeited	(573,980)
Number of stock options, outstanding	20,274,077	21,387,909
Number of stock options, Exercisable	13,363,870
Weighted price per share, outstanding	$ 5.25
Weighted price per share, Granted	5.36
Weighted price per share, Exercised	3.89
Weighted price per share, Forfeited	5.16
Weighted price per share, outstanding	5.31	$ 5.25
Weighted price per share,exercisable	$ 4.46
Weighted contractual term, outstanding	7 years 6 months	7 years 4 months 24 days
Weighted contractual term, exercisable	7 years 1 month 6 days
Aggregate intrinsic value, outstanding	$ 32,167	$ 49,684
Aggregate intrinsic value, exercisable	$ 27,022

Stock-Based Compensation (Summary of Restricted Stock Activity) (Details)	3 Months Ended
	Mar. 31, 2022 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross	303,086
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested, Number of Shares, Begining Balance	0
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross	300,000
Unvested, Number of Shares, Ending Balance	300,000
Unvested, Weighted average grant date fair value per share, beginning balance \| $ / shares	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares	3.76
Unvested, Weighted average grant date fair value per share, ending balance \| $ / shares	$ 3.76

Stock-Based Compensation (Schedule of Stock-Based Compensation Expense for Stock Options) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 2,178	$ 3,440
Research And Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	807	273
General And Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 1,371	$ 3,167

Income Taxes (Narrative) (Details)	3 Months Ended
Income Taxes (Narrative) (Details)	Mar. 31, 2022	Mar. 31, 2021
Operating Loss Carryforwards [Line Items]
Effective Income Tax Rate Continuing Operations	0.00%	0.00%

Net Loss Per Share (Schedule of Excluded Potential Common Shares from Computation of Diluted Net Loss Per Share) (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	22,502,097	19,841,206
Options issued and outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	20,574,077	19,712,504
Warrants issued and outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Excluded potential common shares from computation of diluted net loss per share	1,928,020	128,702

Commitments and Contingencies (Narrative) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($)
Commitments And Contingencies [Line Items]
Project Grant	$ 0.8
Grant, Accrued Liability, Current	0.0
Grant, Accrued Liability, NonCurrent	0.0
Short Term Lease Payments	0.1
Variable Lease Payment	0.1
Contract Research Organizations [Member]
Commitments And Contingencies [Line Items]
Remaining prepayments	3.1
Contract Manufacturing Organizations [Member]
Commitments And Contingencies [Line Items]
Remaining prepayments	$ 2.6

Benefit Plans (Narrative) (Details) - Foreign Plan [Member] - Personal Retirement Savings Account [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Defined Contribution Plan Disclosure [Line Items]
Company contribution percent	4.00%
Company contributions	$ 0.1	$ 0.1

Related Party Transactions (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Due to related parties	$ 16,800		$ 19,400
Service fees	800	$ 8,700
Prepaid expenses	8,183		8,851
Due From Related Parties	$ 400		$ 400
UBI [Member]
Related Party Transaction [Line Items]
Percent of ownership	44.00%

- Definition

For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10(3))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.3)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

+ Details

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.17)
-URI http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(3),(4))
-URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

+ Details

- Definition

Direct costs arising from transactions with related parties who are not affiliates or joint Ventures. These costs are categorized as cost of goods sold.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

+ Details

Related Party Transactions (Schedule of Related Party Operating Activity) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Related Party Transaction [Line Items]
Prepaid expenses and other current assets	$ 8,183		$ 8,851
Due From Related Parties	400		400
Property and equipment, net	12,594		12,173
Due to related parties	16,800		19,400
Accrued expenses	168
Revenue		$ 17
Cost of revenue		1
UBI IP [Member] \| Services Provided By Related Parties [Member]
Related Party Transaction [Line Items]
Prepaid expenses and other current assets	3,546		3,517
Due From Related Parties	399		393
Property and equipment, net	299		337
Due to related parties	16,787		$ 19,407
Reimbursement from related party	$ 784	10,633
General and administrative		507
UBI IP [Member] \| Taiwan CDC Grant [Member]
Related Party Transaction [Line Items]
Reimbursement from related party		$ (2,417)

Subsequent Events (Narrative) (Details) - Subsequent Event [Member] $ in Thousands	1 Months Ended
	Apr. 30, 2022 USD ($) ft²
Subsequent Event [Line Items]
CEPI Funding \| $	$ 9,250
AreaOfRealEstateProperty \| ft²	4,419